CTAS vs KROS · P/E 51, rev $11.26B vs rev $32.0K
Cintas Corporation (CTAS) versus Keros Therapeutics Inc (KROS) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Keros Therapeutics Inc (KROS) is a biotechnology company listed on US.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported KROS revenue for 2026-06-30 was $32.0K. Net income was -$52.4M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. KROS currently screens at market cap $208.8M.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. KROS currently screens at market cap $208.8M.
Not investment advice. Open the CTAS and KROS stock pages for the full models.
Not investment advice.